A Phase II Trial Investigating Vemurafenib for the Treatment of Hairy Cell Leukemia
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
Clinical Pearls
Jae Park, MD, attending physician, Leukemia Service, Memorial Sloan-Kettering Cancer Center, describes the design of a trial analyzing vemurafenib for the treatment of patients with hairy cell leukemia.
- This phase II trial has 13 patients enrolled and is still accruing
- Patients in the trial will receive the same dose of vemurafenib that is approved for the treatment of late-stage melanoma
- Following three cycles of therapy, disease response is assessed, and patients can continue on vemurafenib for three additional cycles
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
